Norman M. Goldfarb

Minimizing the cost of financing receivables could be the difference between growth and decline.

If a future Supreme Court ruling on diversity were to be applicable to clinical research, the FDA’s positions on diversity will take on even more importance.

Developing consensus answers to these questions can aid industry in avoiding duplicative efforts and implementing new ideas more efficiently.

Measuring different dimensions of diversity beforehand can lead to more thoughtful planning and execution.